These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 1311488)

  • 1. Construction of a genetically defined Salmonella typhi Ty2 aroA, aroC mutant for the engineering of a candidate oral typhoid-tetanus vaccine.
    Chatfield SN; Fairweather N; Charles I; Pickard D; Levine M; Hone D; Posada M; Strugnell RA; Dougan G
    Vaccine; 1992; 10(1):53-60. PubMed ID: 1311488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of delta aroA his delta pur strains of Salmonella typhi.
    Edwards MF; Stocker BA
    J Bacteriol; 1988 Sep; 170(9):3991-5. PubMed ID: 2842296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stable expression and immunogenicity in a attenuated Salmonella typhi strain of coli surface antigen-6 of enterotoxigenic Escherichia coli].
    Teng J; Rui X; Zhang Y; Zhang Z; Su G
    Wei Sheng Wu Xue Bao; 1999 Dec; 39(6):533-8. PubMed ID: 12555559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rpoS mutant allele of Salmonella typhi Ty2 is identical to that of the live typhoid vaccine Ty21a.
    Robbe-Saule V; Norel F
    FEMS Microbiol Lett; 1999 Jan; 170(1):141-3. PubMed ID: 9919662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation of stable aroA mutants of Salmonella typhi Ty2: properties and preliminary characterisation in mice.
    Dougan G; Maskell D; Pickard D; Hormaeche C
    Mol Gen Genet; 1987 May; 207(2-3):402-5. PubMed ID: 3039297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of candidate live oral Salmonella typhi vaccine strains harboring defined mutations in aroA, aroC, and htrA.
    Lowe DC; Savidge TC; Pickard D; Eckmann L; Kagnoff MF; Dougan G; Chatfield SN
    Infect Immun; 1999 Feb; 67(2):700-7. PubMed ID: 9916080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel use of anaerobically induced promoter, dmsA, for controlled expression of fragment C of tetanus toxin in live attenuated Salmonella enterica serovar Typhi strain CVD 908-htrA.
    Orr N; Galen JE; Levine MM
    Vaccine; 2001 Feb; 19(13-14):1694-700. PubMed ID: 11166893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of genetically defined double aro mutants of Salmonella typhi.
    Hone DM; Harris AM; Chatfield S; Dougan G; Levine MM
    Vaccine; 1991 Nov; 9(11):810-6. PubMed ID: 1759503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.
    Wang JY; Pasetti MF; Noriega FR; Anderson RJ; Wasserman SS; Galen JE; Sztein MB; Levine MM
    Infect Immun; 2001 Aug; 69(8):4734-41. PubMed ID: 11447145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors.
    Khan SA; Stratford R; Wu T; Mckelvie N; Bellaby T; Hindle Z; Sinha KA; Eltze S; Mastroeni P; Pickard D; Dougan G; Chatfield SN; Brennan FR
    Vaccine; 2003 Jan; 21(5-6):538-48. PubMed ID: 12531654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of phoP and rpoS mutants of Salmonella enterica serovar Typhi as attenuated typhoid vaccine candidates: virulence and protective immune responses in intranasally immunized mice.
    Lee HY; Cho SA; Lee IS; Park JH; Seok SH; Baek MW; Kim DJ; Lee SH; Hur SJ; Ban SJ; Lee YK; Han YK; Cho YK; Park JH
    FEMS Immunol Med Microbiol; 2007 Nov; 51(2):310-8. PubMed ID: 17725620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A murine model of intranasal immunization to assess the immunogenicity of attenuated Salmonella typhi live vector vaccines in stimulating serum antibody responses to expressed foreign antigens.
    Galen JE; Gomez-Duarte OG; Losonsky GA; Halpern JL; Lauderbaugh CS; Kaintuck S; Reymann MK; Levine MM
    Vaccine; 1997; 15(6-7):700-8. PubMed ID: 9178472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive acid tolerance response by Salmonella typhi and candidate live oral typhoid vaccine strains.
    Hone DM; Harris AM; Levine MM
    Vaccine; 1994 Aug; 12(10):895-8. PubMed ID: 7975830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of plasmid stability on oral DNA delivery by Salmonella enterica serovar Typhimurium.
    Gahan ME; Webster DE; Wesselingh SL; Strugnell RA
    Vaccine; 2007 Feb; 25(8):1476-83. PubMed ID: 17126961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic detoxification of an aroA Salmonella enterica serovar Typhimurium vaccine strain does not compromise protection against virulent Salmonella and enhances the immune responses towards a protective malarial antigen.
    McKelvie ND; Khan SA; Karavolos MH; Bulmer DM; Lee JJ; DeMarco R; Maskell DJ; Zavala F; Hormaeche CE; Khan CM
    FEMS Immunol Med Microbiol; 2008 Mar; 52(2):237-46. PubMed ID: 18177343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and characterization of vaccine strains of Salmonella harboring mutations in two different aro genes.
    Dougan G; Chatfield S; Pickard D; Bester J; O'Callaghan D; Maskell D
    J Infect Dis; 1988 Dec; 158(6):1329-35. PubMed ID: 3058818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers.
    Kirkpatrick BD; McKenzie R; O'Neill JP; Larsson CJ; Bourgeois AL; Shimko J; Bentley M; Makin J; Chatfield S; Hindle Z; Fidler C; Robinson BE; Ventrone CH; Bansal N; Carpenter CM; Kutzko D; Hamlet S; LaPointe C; Taylor DN
    Vaccine; 2006 Jan; 24(2):116-23. PubMed ID: 16140433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a phoP/phoQ-deleted, aroA-deleted live oral Salmonella typhi vaccine strain in human volunteers.
    Hohmann EL; Oletta CA; Miller SI
    Vaccine; 1996 Jan; 14(1):19-24. PubMed ID: 8821644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as "carrier" vaccines.
    Levine MM; Hone D; Tacket C; Ferreccio C; Cryz S
    Res Microbiol; 1990; 141(7-8):807-16. PubMed ID: 2101470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and immunogenicity in mice of attenuated Salmonella typhi expressing Plasmodium falciparum merozoite surface protein 1 (MSP-1) fused to tetanus toxin fragment C.
    Wu S; Beier M; Sztein MB; Galen J; Pickett T; Holder AA; Gómez-Duarte OG; Levine MM
    J Biotechnol; 2000 Sep; 83(1-2):125-35. PubMed ID: 11000468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.